Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trialAlexander P. J. Vlaar, Leo Heunks, Bruno Mourvillier et al.|The Lancet Respiratory Medicine|2022Cited by 143
ICONIC study—conservative versus conventional oxygenation targets in intensive care patients: study protocol for a randomized clinical trialChloe C.A. Grim, Iole Brunetti, Lea Imeen van der Wal et al.|Trials|2022Cited by 6